.png)
Podcast with MedAsian
China healthcare policy landscape
Podcast with MedAsian
Latest Episodes
Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part I)
Surge drivers: Advances in deep learning and large language models, mounting pressure from aging populations and rising costs, plus heavy investment and government backing are converging to make AI a practical, system-shaping force in heal...
.png)
From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map (Part 2)
For multinational pharma in China: A strategic trade-off emerges between US market access and global efficiency. High tariffs penalize offshore production, pushing firms from “China for Global” to “China for China” models. Expect more US-b...
From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map
What is Section 232? A U.S. trade law allowing the President to restrict imports deemed a threat to "national security." It is now being applied to pharmaceuticals, reframing medicine as a strategic asset rather than just a commerci...
Policy advocacy, government relations, and bilateral investment opportunities in an evolving US-China landscape (Part 2)
A quick summary of this episode.US-China relations: Managed competition with selective decoupling, not full decoupling. Upcoming Trump visit expected to be transactional, not a dramatic reset.Bilateral investment<...
Policy advocacy, government relations, and bilateral investment opportunities
In this MedAsian podcast episode, Director of Government Affairs Felix Li shares insights from a two-week trip to Washington, D.C., outlining the evolving US-China landscape and what it means for multinational businesses.Selectiv...